Array Biopharma (ARRY) Tops Q4 EPS by 4c

Array Biopharma (NASDAQ: ARRY) reported Q4 EPS of ($0.17), $0.04 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $33.8 million versus the consensus estimate of $28.61 million.

Cash, Cash Equivalents and Marketable Securities as of June 30, 2017 were $235.1 million.

For earnings history and earnings-related data on Array Biopharma (ARRY) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M